Roundup: Houston startups announce new partnerships, crowdfunding campaigns, and more

Short stories

A Houston tech startup launches a crowdfunding campaign — and more local innovation news. Photo courtesy of The Postage

The Houston innovation ecosystem has been bursting at the seams with news from innovative tech companies and disruptive Houston startups as we fly through the final quarter of 2021.

In this roundup of short stories within Houston innovation, a Texas energy tech company gets selected for a prestigious program, a med device company heads to clinical trials, a startup launches a crowdfunding campaign, and more.

The Postage launches crowdfunding campaign

The Postage is looking for financial support with its new campaign. Photo courtesy of The Postage

The Postage, a Houston-based, full-service digital platform to help organize affairs to make after-life planning a smoother process for families, has announced the launch of a crowdfunding campaign through MicroVentures.

"This crowdfunding offering is selling crowd notes to raise maximum offering proceeds of $500,000 with a minimum investment of $100," according to a news release. "We currently anticipate closing this offering on April 4, 2022."

More information on this offering can be found at: https://invest.microventures.com/offerings/the-postage.

Emily Cisek co-founded the company after she experienced an overwhelming experience following a death in her family.

"I just knew there had to be a better way, and that's why I started The Postage," Cisek says on an episode of the Houston Innovators Podcast. "My background had historically been in bringing offline businesses online, and I started doing some research on how I could make this space better. At the time, there really wasn't anything out there."

Texas company selected for Chevron Technology Ventures Catalyst Program

This Texas company has joined CTV's startup program. Photo via Getty Images

SeebeckCell Technologies, while based in Arlington, Texas, is no stranger to the Houston innovation ecosystem. The startup was in the first class of the Rice Alliance Clean Energy Accelerator, participated in the MassChallenge Texas Houston cohort, and is a member at Greentown Houston. The company announced earlier this month a new Houston association as it was invited to participate in the Chevron Technology Ventures Catalyst Program to develop further their technology platform designed to recover industrial waste heat energy, increasing energy consumption efficiency, and eliminating battery replacement in IoT applications, according to a news release.

"SeebeckCell is excited to be supported by Chevron, a technology leader in the energy market," says Ali Farzbod, co-founder and CEO of Seebeckcell Technologies, in the release. "This is inspiring hope in the scientific community as we see Chevron continue to back commercializing academically developed technologies that provide potential solutions for addressing climate change. Through collaboration and partnership, we're able to grow our startup and we're grateful for participating in the Rice Alliance Clean Energy Accelerator that helped connect us with Chevron."

SeebeckCell Technologies is helping petroleum and gas industries and emerging markets solve energy waste with an innovative liquid based thermoelectric generator.

VenoStent heads to clinical trials

VenoStent

VenoStent has reached the clinical trials stage. Photo via venostent.com

VenoStent Inc. has announced successful enrollment in its initial feasibility clinical trial. The med device startup is a tissue engineering company that's developing smart polymer wraps to transform the efficacy of the vascular surgery industry, which sees five million operations each year.

"We are very pleased to announce that we have successfully enrolled twenty end-stage renal disease patients in our initial feasibility study taking place in Asuncion, Paraguay," says Tim Boire, CEO., in a news release "After years of development, we are confident that our bioabsorbable wrap technology can have a positive impact on the lives of patients that require hemodialysis to sustain life. This is a major milestone toward our mission to improve the quality and length of life for end-stage renal disease patients, as well as others needing vascular surgery."

VenoStent is an alum of TMC Innovation's accelerator and has been named a most promising company by Rice Alliance.

Cart.com announces latest partnership

Cart.com has a new partner, which has increased access to tools for its clients. Photo via cart.com

Houston-based Cart.com, an end-to-end ecommerce services provider and Amazon competitor, has announced yet another new partnership. The company has teamed up with Extend, which provides modern extended warranties and product protection plans. The partnership means that Cart.com merchants have access to a new revenue stream and new ways to increase customer satisfaction by leveraging Extend's platform and technology-enabled proprietary insurance stack.

"Like Cart.com, Extend is fixing the fractured ecommerce ecosystem by providing a truly innovative, effortless, and easy-to-understand service for both merchants and their customers," says Omair Tariq, Cart.com co-founder and CEO, in a news release. "By creating seamless solutions to serve brands, we empower them to focus completely on their customers. The partnership with Extend fits squarely in this view; anyone who has wrangled with extended warranty claims in the past understands the friction involved. Extend is rewriting the rules for product protection and customer service while Cart.com takes care of everything from the factory floor to the customer door. Through this partnership with Extend, we're now seamlessly covering the post-purchase experience too."

Extend launched in 2019 — a time when only the top 1 percent of merchants could offer extended warranties and protection plans to help their customers, according to the release. Now, Extend is valued at $1.6 billion, has raised over $315 million in venture capital, is on track to sell more than three million protection plans in 2021.

"The relationship between an ecommerce company and its customer doesn't end with the sale," says Woodrow Levin, co-founder and CEO of Extend, in the release. "Our technology will allow Cart.com's clients to continue to engage customers after they make a purchase, unlocking opportunities to increase brand loyalty, open new revenue channels, and create lasting customer relationships. Together, we're empowering clients to deliver a better experience for customers and we are excited to continue to build on that vision."

Campus Concierge rebrands to Clutch with revamped website

A Houston startup has just flipped a switch. Image via thatsclutch.com

Campus Concierge is now Clutch, the Houston-based startup announced on its Facebook page last month. The new name also came with a revamped website.

Madison Long and Simone May had the idea for the company when they were undergraduate students at Purdue University and their only option for scoping out basic services — like getting their hair done or hiring a DJ for an event or a photographer for graduation photos — was to ask around among older students. Launched earlier this year, the platform is a marketplace to connect students who have skills or services with potential clients in a safe way. The company, which was a member of DivInc's inaugural Houston accelerator, launched on three college campuses this year — Texas Southern University, Rice University, and Prairie View A&M.

"Building community is so critical given the fact that it's nerve-wracking any time to ask someone for help — especially now that you are coming back to school after a year of being virtual," Long, CEO and co-founder of Clutch, previously told InnovationMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings